New blood test detects 90% of aggressive prostate cancer cases, beating current screenings
A new blood test, Stockholm3, is outperforming traditional PSA screenings by detecting 90% of aggressive prostate cancer cases.
📍 How it ended
A new blood test, identified as Stockholm3, outperformed PSA alone in detecting clinically significant and aggressive prostate cancer. This screening tool became available locally and was developed through research into DNA-based approaches.
The story quieted without a definitive conclusion in the coverage.
Epilogue added 35d ago, after coverage quieted.
Questions people are asking
What is the name of the new blood test?
The test is called Stockholm3.
How does Stockholm3 compare to the PSA test?
According to coverage, Stockholm3 detected more significant prostate cancers and beats current screenings by detecting 90% of aggressive cases.
Who is researching DNA-based approaches to detection?
Researchers from India and New Zealand are exploring these approaches.
What happened
A new blood test known as Stockholm3 has demonstrated the ability to detect 90% of aggressive prostate cancer cases. This performance exceeds that of current screenings, specifically the PSA test.
Coverage from Fox News, Conexiant, and Oncodaily emphasizes the test's ability to detect more significant cancers than the PSA method. Additionally, BioSpectrum Asia reports that researchers from India and New Zealand are exploring a DNA-based approach to further improve detection.
Future developments involve the continued exploration of DNA-based detection methods and ongoing comparisons between Stockholm3 and PSA screening performance.
Synthesized by Newsylist from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 45d ago.
Coverage (9)
- Multivariable Screening Tool Outperforms PSA Alone in Detecting Clinically Significant Prostate Cancer Newswise · 45d ago
- A new, safer way to check for prostate cancer is now available locally Boise State Public Radio · 45d ago
- Pioneering screening test offers potential to find more aggressive prostate cancers The Manila Times · 45d ago
- Breakthrough blood test detects aggressive prostate cancer | Tap to know more Inshorts · 45d ago
- Next-Generation Blood Test Improves Detection of Aggressive Prostate Cancer HealthDay · 45d ago
- Indo-NZ researchers explore DNA-based approach to improve prostate cancer detection BioSpectrum Asia · 45d ago
- Adam B. Weiner: Can Stockholm3 Outperform PSA for Prostate Cancer Screening? Oncodaily · 45d ago
- Stockholm3 Detected More Significant Prostate Cancers Than PSA Conexiant · 45d ago
- New blood test detects 90% of aggressive prostate cancer cases, beating current screenings Fox News · 45d ago broke it first
The coverage curve
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
People, places & organizations
Topics
Related trends
CRISPR makes prostate cancer vulnerable to immunotherapy
New CRISPR gene-editing research indicates a method to improve the immune system's ability to detect and target prostate cancer tumors.
Only 13% survive this cancer. A blood test just detected 90% of early cases
A new blood gene test has demonstrated the ability to detect 90% of early-stage pancreatic cancers, a disease with a 13% survival rate.
From doctor to patient: Retired radiologist undergoes robotic surgery for prostate cancer
Medical experts are highlighting the critical role of early detection and robotic surgery as prostate cancer cases rise beyond metropolitan areas.
Second prostate-specific membrane antigen PET scan can change treatment for nearly half of prostate cancer patients
A second PSMA PET scan may alter the treatment course for nearly 50% of prostate cancer patients, according to new study data.
'Endometriosis tests would have given me years back'
New diagnostic testing methods using saliva and blood analysis are emerging as potential alternatives for identifying endometriosis.
Is testosterone replacement a fix for the blahs of aging?
A shift in government policy regarding testosterone therapy is sparking a debate over the treatment of age-related hormone decline.